Positive Phase IIb data from AstraZeneca in lupus and RA but PhIII not assured
This article was originally published in Scrip
Executive Summary
AstraZeneca's MedImmune unit has presented positive Phase IIb data at the American College of Rheumatology (ACR) meeting this week from two products highlighted by CEO Pascal Soriot as 'ones to watch' as he fended off Pfizer's unwanted advances earlier this year (scripintelligence.com, 28 May 2014). However, their progress into Phase III is not assured as AstraZeneca is waiting on data from other trials before making a decision on how to proceed.
You may also be interested in...
IPO Update: Returns Halved As Two Biopharmas Go Public In April; Unity Is May's First
Only two drug developers launched offerings in April and the average 2018 IPO return was just 9% – half the first quarter average – at the end of last month. Unity's May 1 offering was the 17th biopharma IPO this year.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.